Tweet
Dry eye drug developments hopefully are enlarging with unfortunate increasing demand:
"Allegro Ophthalmics has added ALG-1007, a new anti-integrin drug candidate for the treatment of dry eye disease, to its portfolio, the company announced in a press release.
The topical agent is under evaluation in a phase 2 study outside of the U.S. and is the company’s first exploratory drug not in the retina space.
“While we remain focused on and committed to our retina portfolio, we at Allegro are continuously exploring new ways to apply our anti-integrin assets to help improve patients’ vision,” Vicken Karageozian, MD, president and CEO of Allegro Ophthalmics, said.
The company has also formed a cornea scientific advisory board “to provide strategy and direction on Allegro’s clinical development pipeline in the areas of corneal disease and dry eye,” the press release said. Richard L. Lindstrom, MD, Edward J. Holland, MD, and Eric D. Donnenfeld, MD, have joined the board.
“We recognize the need to bring in independent external expertise that complements our company’s strengths and are thrilled to have such an outstanding group of advisors,” Karageozian said."
https://www.healio.com/ophthalmology...=2404801039954
"Allegro Ophthalmics has added ALG-1007, a new anti-integrin drug candidate for the treatment of dry eye disease, to its portfolio, the company announced in a press release.
The topical agent is under evaluation in a phase 2 study outside of the U.S. and is the company’s first exploratory drug not in the retina space.
“While we remain focused on and committed to our retina portfolio, we at Allegro are continuously exploring new ways to apply our anti-integrin assets to help improve patients’ vision,” Vicken Karageozian, MD, president and CEO of Allegro Ophthalmics, said.
The company has also formed a cornea scientific advisory board “to provide strategy and direction on Allegro’s clinical development pipeline in the areas of corneal disease and dry eye,” the press release said. Richard L. Lindstrom, MD, Edward J. Holland, MD, and Eric D. Donnenfeld, MD, have joined the board.
“We recognize the need to bring in independent external expertise that complements our company’s strengths and are thrilled to have such an outstanding group of advisors,” Karageozian said."
https://www.healio.com/ophthalmology...=2404801039954